Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
A late-stage trial of Genmab’s petosemtamab hit its co-primary endpoints at the first interim analysis, the biotech said Wednesday, completing…
Category: Genmab
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
Genmab’s FRα-directed antibody-drug conjugate has improved survival in a Phase 3 study, putting the biotech on track to challenge AbbVie…